Latest HealthCare Headlines

2016

August 29, 2016
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement

January 11, 2016
Tensha Therapeutics To Be Acquired By Roche

2015

October 9, 2015
Adheron Therapeutics to be acquired by Roche

March 15, 2015
Targacept and Catalyst Biosciences Enter Definitive Merger Agreement

March 14, 2015
GlobeImmune Announces Program Updates and Financial Results for Full Year 2014

March 9, 2015
Cleveland HeartLab Inc. Launches New Medical

March 9, 2015
Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure

March 2, 2015
Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock

February 25, 2015
Xencor, Inc. Prices Public Offering of Common Stock

February 23, 2015
Xencor, Inc. Announces Proposed Public Offering of Common Stock

February 15, 2015
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines

February 9, 2015
Vaxxas Raises A$25 Million [US$20 Million] in Series B Venture Financing to Accelerate Commercialization of Novel Vaccine Platform

February 9, 2015
Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain

February 4, 2015
Proteostasis Therapeutics Announces a New Class of Agents for Cystic Fibrosis

February 2, 2015
Nicox signs exclusive license agreement with InSite Vision for AzaSiteÆ and BromSiteô in Europe

January 29, 2015
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis

January 29, 2015
Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers

January 26, 2015
Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package

January 22, 2015
Radius Health, Inc. Announces Pricing of Public Offering

January 6, 2015
Trevena Initiates Second Phase 2b Study of TRV130 for Acute Postoperative Pain